An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age2+
SponsorGustave Roussy, Cancer Campus, Grand Paris

About this trial

This is a study to explore the phenotypic and transcriptional changes of different cellular components in the tumor following the injection of somatic cell therapy drugs.

The second objective is to explore phenotypic and transcriptional changes of different cellular components in blood and bone marrow following injection of somatic cell therapy drugs.Then correlate the phenotypic and transcriptional profile of different tumor, blood and bone marrow immune populations with clinical response and/or toxicity. And to finish this study is designed in order to identify a phenotypic, transcriptional and epigenetic profile of intra-tumoral adoptive cells and correlate this profile with clinical response and/or toxicity.

Eligibility criteria

Qualifiers

Patient affiliated to a social security regimen

Tumor lesion accessible to core biopsies

Patient who is fully informed, able to comply with the protocol and who signed the informed consent

Pediatric patients > than 2 years old can be included

Disqualifiers

Coagulation abnormality prohibiting a biopsy (but patients can still give their consent for blood and bone marrow samples).

Tumor lesion not accessible to core biopsies.

Pregnant or nursing women cannot participate in this study.

Trial design

Treatments tested in this trial

  • Tumor biopsy
  • Blood sample
  • Bone marrow sample

Treatment groups

160 Participants
are divided into 1 treatment group